Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 12, 2005, Pages 4911-4919

  Strizki, Julie M ^a   Tremblay, Cecile ^b   Xu, Serena ^a   Wojcik, Lisa ^a   Wagner, Nicole ^a   Gonsiorek, Waldemar ^a   Hipkin, R William ^a   Chou, Chuan Chu ^a   Pugliese Sivo, Catherine ^a   Xiao, Yushi ^a   Tagat, Jayaram R ^a   Cox, Kathleen ^a   Priestley, Tony ^a   Sorota, Steve ^a   Huang, Wei ^c   Hirsch, Martin ^b   Reyes, Gregory R ^a   Baroudy, Bahige M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ANTIRETROVIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; POTASSIUM CHANNEL HERG; VICRIVIROC; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; CHEMOTAXIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5;

EID: 28944454412     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.12.4911-4919.2005     Document Type: Article

References (26)

1. Cheng, Y., and W. H. Prusoff. 1973. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzyme reaction. Biochem. Pharmacol. 22:3099-3108.
2. Chou, T. C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T. C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
3. Cox, M. A., C.-H. Jenh, W. Gonsiorek, J. Fine, S. K. Narula, P. J. Zavodny, and R. W. Hipkin. 2001. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell α chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol. Pharmacol. 59:707-715.
4. Doms, R. W. 2001. Chemokine receptors and HIV entry. AIDS 15(Suppl. 1):S34-S35.
5. Doms, R. W., and J. P. Moore. 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:F9-F14.
6. Eron, J. J., R. M. Gulick, J. A. Bartlett, T. Merigan, R. Arduino, J. M. Kilby, B. Yangco, A. Diers, C. Drobnes, R. DeMasi, M. Greenberg, T. Melby, C. Raskino, P. Rusnak, Y. Zhang, R. Spence, and G. D. Miralles. 2004. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J. Infect. Dis. 189:1075-1083.
7. Este, J. A. 2003. Virus entry as a target for anti-HIV intervention. Curr. Med. Chem. 10:1617-1632.
8. Finlayson, K., H. J. Witchel, J. McCulloch, and J. Sharkey. 2004. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol. 500:129-142.
9. Greenberg, M. L., and N. Cammack. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54:333-340.
10. Hendrix, C. W., A. C. Collier, M. M. Lederman, D. Schols, R. B. Pollard, S. Brown, J. B. Jackson, R. W. Coombs, M. J. Glesby, C. W. Flexner, G. J. Bridger, K. Badel, R. T. MacFarland, G. W. Henson, and G. f. t. A. H. S. G. Calandra. 2004. Safety, pharmacokinetics and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immun. Defic. Syndr. 37:1253-1262.
11. Jacobson, J. M., R. J. Israel, I. Lowy, N. A. Ostrow, L. S. Vassilatos, M. Barish, D. N. Tran, B. M. Sullivan, T. J. Ketas, T. J. O'Neill, K. A. Nagashima, W. Huang, C. J. Petropoulos, J. P. Moore, P. J. Maddon, and W. C. Olson. 2004. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. 48:423-429.
12. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
13. Lalezari, J. P., M. Thompson, P. Kumar, P. Piliero, R. Davey, K. Patterson, A. Shachoy-Clark, K. Adkison, J. Demarest, Y. Lou, M. Berrey, and S. Piscitelli. 2005. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19:1443-1448.
14. Lazzarin, A., B. Clotet, D. Cooper, J. Reynes, K. Arasteh, M. Nelson, C. Katlama, H.-J. Stellbrink, J.-F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drobnes, M. Salgo, and the TORO 2 Study Group. 2003. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348:2186-2195.
15. Lin, P.-F., W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y.-F. Gong, H.-G. H. Wang, R. Rose, G. Yamanaka, B. Robinson, C.-B. Li, R. Fridell, C. Deminie, G. Demers, Z. Yang, L. Zadjura, N. Meanwell, and R. Colonno. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA. 100:11013-11018.
16. Maeda, K., H. Nakata, H. Ogata, Y. Koh, T. Miyakawa, and H. Mitsuya. 2004. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV infection. Curr. Opin. Pharmacol. 4:447-452.
17. Palani, A., S. Shapiro, J. W. Clader, W. J. Greenlee, K. Cox, J. Strizki, M. Endres, and B. M. Baroudy. 2001. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1′-[(2,4-dimethyl-3-pyridinyl)carbonyl] -4′-methyl-1,4′-bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J. Med. Chem. 44:3339-3342.
18. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
19. Redtern, W. S., L. Carlsson, A. S. Davis, W. G. Lynch, I. MacKenzie, S. Palenthorpe, P. K. S. Siegl, I. Strang, A. T. Sullivan, R. Wallis, A. J. Camm, and T. G. Hammond. 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58:32-45.
20. Root, M. J., M. S. Kay, and P. S. Kim. 2001. Protein design of an HIV-1 entry inhibitor. Science 291:884-888.
21. Strizki, J. M., S. Xu, N. E. Wagner, L. Wojcik, J. Liu, Y. Hou, M. Endres, A. Palani, S. Shapiro, J. W. Clader, W. J. Greenlee, J. R. Tagat, S. McCombie, K. Cox, A. B. Fawzi, C. C. Chou, C. Pugliese-Sivo, L. Davies, M. E. Moreno, D. D. Ho, A. Trkola, C. A. Stoddart, J. P. Moore, G. R. Reyes, and B. M. Baroudy. 2001. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98:12718-12723.
22. Tagat, J. R., S. W. McCombie, D. Nazareno, M. A. Labroli, Y. Xiao, R. W. Steensma, J. M. Strizki, B. M. Baroudy, K. Cox, J. Lachowicz, G. Varty, and R. Watkins. 2004. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4- (trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]-4-methyl-piperidine (Sch-4I7690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J. Med. Chem. 47:2405-2408.
23. Tagat, J. R., S. W. McCombie, R. W. Steensma, S. Lin, D. V. Nazareno, B. Baroudy, N. Vantuno, S. Xu, and J. Liu. 2001. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. 11:2143-2146.
24. Tremblay, C. L., F. Giguel, C. Kollmann, Y. Guan, T. C. Chou, B. M. Baroudy, and M. S. Hirsch. 2002. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46:1336-1339.
25. United Kingdom Collaborative Group on HIV Drug Resistance. 2005. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J. Infect. Dis. 192:967-973.
26. Wild, C., D. Shugars, T. Greenwell, C. McDanal, and T. Matthews. 1994. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.